EU grants orphan status to OXiGENE's ovarian cancer drug

OXiGENE's experimental ovarian cancer drug Zybrestat obtained orphan-drug designation from the European Medicines Agency. The drug, in combination with Roche Holding's Avastin, is in a midstage study for patients with advanced ovarian cancer. Data from the trial could be released next year.

View Full Article in:

Wall Street Journal (tiered subscription model), The · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA